Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | TP53 | P04637 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.34 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2656741 | 0.80 | ALDH1A1 (0.38) | ALDH1A1SMN1; SMN2MAPTTP53KDM4E | |
| SCHEMBL3843752 | 0.71 | — | — | |
| SCHEMBL11617 | 0.70 | FDPS (0.33) | TSHRNPC1 | |
| SCHEMBL29092717 | 0.70 | MEN1 (0.43) | ALDH1A1KDM4EMEN1KMT2AMAPK1 | |
| SCHEMBL15032983 | 0.70 | DGAT1 (0.32) | NPC1 | |
| Ammonia Solution, Strong SCHEMBL27898568 | 0.69 | FDPS (0.32) | TSHR | |
| SCHEMBL10505307 | 0.69 | CYP19A1 (0.42) | ALDH1A1SMN1; SMN2MAPTKDM4ECYP19A1 | |
| SCHEMBL4606038 | 0.68 | DGAT1 (0.34) | MAPTNPC1 | |
| SCHEMBL24306335 | 0.68 | DGAT1 (0.35) | — | |
| SCHEMBL3500693 | 0.68 | DGAT1 (0.38) | SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4713320-A2 | BCAT2 INHIBITORS | Agios Pharmaceuticals, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| WO-2025235874-A1 | HETEROCYCLICS AS EGFR INHIBITORS | SCHRÖDINGER, INC. (US) | 2025-11-13 | — | — | WO | disclosed |
| US-20250230147-A1 | LACTAMS AS CBL-B INHIBITORS | GENENTECH, INC. (US) | 2025-07-17 | — | — | US | disclosed |
| WO-2025021997-A1 | NEW MAP4K1 INHIBITORS | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2025-01-30 | — | — | WO | disclosed |
| US-20240382483-A1 | HETEROCYCLIC EGFR INHIBITORS FOR USE IN THE TREATMENT OF CANCER | BLUEPRINT MEDICINES CORPORATION | 2024-11-21 | — | — | US | disclosed |
| WO-2024238820-A2 | BCAT2 INHIBITORS | AGIOS PHARMACEUTICALS, INC. (US) | 2024-11-21 | — | — | WO | disclosed |
| EP-4430036-A2 | BCAT2 INHIBITORS | Agios Pharmaceuticals, Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| US-20240208965-A1 | HETEROARYL ALKYLENE SUBSTITUTED 2-OXOQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS | IDEAYA BIOSCIENCES, INC. | 2024-06-27 | — | — | US | disclosed |
| US-20240174683-A1 | MAP4K1 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2024-05-30 | — | — | US | disclosed |
| EP-3694846-B1 | 1-BENZYL-2-IMINO-4-PHENYL-5-OXOIMIDAZOLIDINE DERIVATIVES AS HIV PROTEASE INHIBITORS | GILEAD SCIENCES INC (US) | 2024-05-08 | — | — | EP | disclosed |
| WO-2017194716-A1 | INHIBITORS OF PROTEASE-ACTIVATED RECEPTOR-2 | ASTRAZENECA AB (SE) | 2017-11-16 | — | — | WO | disclosed |
| EP-1343788-B1 | IMIDAZO-TRIAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME (GB) | 2005-11-23 | — | — | EP | disclosed |
| US-6936608-B2 | Imidazo-triazine derivatives as ligands for GABA receptors | MERCK SHARP & DOHME LTD. | 2005-08-30 | — | — | US | disclosed |
| US-20040023964-A1 | Imidazo-triazine derivatives as ligands for gaba receptors | MERCK SHARP & DOHME LTD. (GB) | 2004-02-05 | — | — | US | disclosed |
| US-6444666-B1 | SUCH AS ALZHEIMER'S DISEASE; SUBSTITUTED 1,2,4-TRIAZOLO(4,3-B) PYRIDAZINE DERIVATIVES ARE LIGANDS FOR GABA RECEPTORS; CONVULSANT ACTIVITY IS REDUCED OR ELIMINATED | MERCK SHARP & DOHME LTD. (GB) | 2002-09-03 | — | — | US | disclosed |
| EP-0986562-B1 | SUBSTITUTED 1,2,4-TRIAZOLO 3,4-A]PHTHALAZINE DERIVATIVES AS GABA ALPHA 5 LIGANDS | MERCK SHARP & DOHME (GB) | 2002-08-07 | — | — | EP | disclosed |
| US-6310203-B1 | Precursor compounds to substituted 1,2,4-triazolo[3,4,-a]phathalazine GABA alpha 5 ligands | MERCK SHARPE & DOHME LIMITED (GB) | 2001-10-30 | — | — | US | disclosed |
| US-6255305-B1 | PSYCHOLOGICAL DISORDERS | MERCK SHARP & DOHME LIMITED (GB) | 2001-07-03 | — | — | US | disclosed |
| US-6200975-B1 | FOR COGNITION ENHANCEMENT THERAPY | MERCK SHARP & DOHME LIMITED (GB) | 2001-03-13 | — | — | US | disclosed |
| CN-1251589-A | Substituted triazolopyridazine derivatives as ligands for GABA receptors | MERCK SHARP & DOHME (GB) | 2000-04-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250230147-A1 | LACTAMS AS CBL-B INHIBITORS | CBLB, CBL, CBLC | ALDH1A1 4354/4885SMN1; SMN2 3071/4885MAPT 2738/4885 |
| US-20240174683-A1 | MAP4K1 INHIBITORS | MAP3K4, MAP4K4, MAP4K1 | ALDH1A1 3841/4885SMN1; SMN2 1949/4885MAPT 120/4885 |
| US-20040023964-A1 | Imidazo-triazine derivatives as ligands for gaba receptors | GABRA2, GABRA5, GABRA1 | ALDH1A1 646/4885SMN1; SMN2 1518/4885MAPT 517/4885 |
| US-20240208965-A1 | HETEROARYL ALKYLENE SUBSTITUTED 2-OXOQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS | MAT2A, MAT2B, MAT1A | ALDH1A1 874/4885SMN1; SMN2 1694/4885MAPT 2203/4885 |
| US-20240382483-A1 | HETEROCYCLIC EGFR INHIBITORS FOR USE IN THE TREATMENT OF CANCER | EGFR, ERBB2, ERBB4 | ALDH1A1 1221/4885SMN1; SMN2 4605/4885MAPT 4071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.